FBS required for cell culture maintenance
Ended Awarded
- Contract number
- 75N91022F00001
- Awardee
-
Gemini Bioproducts LLC UEI TPLGWKT6AM88
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $24,206
Award facts
- Contract value 100% obligated
- $24,205.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Broderick, CA 95605, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a $24.2K firm fixed-price Blanket Purchase Agreement (BPA) call to Gemini Bioproducts LLC for fetal bovine serum (FBS) required for cell culture maintenance. The contract was executed on August 10, 2022, with an ultimate completion date of September 9, 2022, and performed at the contractor's facility in West Sacramento, California. This award was not issued under any small business set-aside designation. Gemini Bioproducts, a long-established supplier of cell culture products and biological reagents headquartered in California, drew on its extensive track record providing critical research materials to National Institutes of Health agencies.
This procurement represents a routine replenishment call against one of Gemini Bioproducts' existing Blanket Purchase Agreements with the federal government. The contractor maintains a $100 million single-award BPA with the Office of Logistics and Acquisition Operations that provides cell culture products, sera, antibiotics, media, reagents, and blood-related products to support biomedical research across multiple federal agencies. FBS is a fundamental component in cell culture applications used in cancer research, vaccine development, and other scientific investigations conducted or supported by the National Cancer Institute, making reliable supply of this material essential to federal research operations.
Quick answers
Who was awarded contract 75N91022F00001?
75N91022F00001 was awarded to Gemini Bioproducts LLC by National Cancer Institute (National Institutes of Health) on August 10, 2022.
How much is contract 75N91022F00001 worth?
The government has obligated $24,206 on 75N91022F00001.
Is contract 75N91022F00001 an order under another contract?
Yes. 75N91022F00001 is a BPA call under HHSN263201500189B, a blanket purchase agreement.
Was contract 75N91022F00001 competed?
The extent of competition for 75N91022F00001 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award